Roche’s Hivid
Executive Summary
Antivirals committee will discuss "newly available data on the safety and efficacy of zalcitabine...when used as a monotherapy and when used as one agent of a combination therapy" on Sept. 20 at Parklawn. Hivid (ddC) received an accelerated approval for use in combination therapy in June 1992 ("The Pink Sheet" June 29, 1992, p. 10). The committee meeting will begin at 8 a.m. both days.